WHY GNBT COULD MOVE BIG SOON
October 23, 2019 -- InvestorsHub NewsWire -- via Seeking
Alpha
Oct. 23, 2019 10:05 AM ET|About: Generex Biotechnology Corp. (GNBT), GNBT
Originaly Published On Seeking Alpha: www.seekingalpha.com/GNBT
- Big win for GNBT shareholders as upcoming 1 for 1
dividend expected to be paid ONLY to float shareholders in
next few days. Shareholders must hold shares through October 30,
2019 to receive dividend.
- Sellers before October 30, 2019 lose the dividend.
- Up list to NASDAQ and dividend expected by October 30, 2019 is
likely to attract large institutional investors.
- Share price could run in next few days as investors discover
dividend may be close to being paid.
- Over $173 Billion for 14 deals paid by Big Pharma
acquisitions for first half 2019 dominated by cancer
drugs. Average deal was $12.3 Billion.
- GenerexA37 Breast Cancer
Vaccine attracted Merck because it demonstrates high
efficacy with low adverse side effects against many common
cancers.
- Upfront license
payments for AE37 by Shenzhen BioScien Pharmaceuticals for
Prostate Cancer in China, Taiwan, Hong Kong and Macau.
- GNBT’s A37 Cancer Vaccine held by NuGenerex Immuno-Oncology
expected to begin publicly trading by end of November 2019 creating
valuable liquidity for GNBT and shareholders.
Summary
Several events are expected to occur in a very short-term window
that could send Generex Biotechnology Corporation (GNBT:
OTC) share price substantially higher.
Generex confirmed that the record date for the 1:1 (100%) stock
dividend was recorded on August 30, 2019, and the dividend will be
paid on October 29th to all shareholders who hold
their shares through the ex-date of October 30, 2019. Anyone who
sells their shares before the market close on October
30th will lose the dividend, which will be
transferred to the buyer of your shares, just as anyone buying
shares from now through October 30th will receive
the 1:1 (100%) dividend from the seller of the shares.Management
and company insiders, note holders, acquisition partners, and the
pool shares controlled by Generex President & CEO Joe Moscato
on behalf of the Pool owners have waived their rights to the
dividend. Therefore, if any of these entities or persons sells
their shares, they will receive a “Pay Due Bill” and personally owe
the dividend shares to the buyer, which is their sole
responsibility to pay; Generex will not pay the dividend for those
who have waived the dividend.
Mr. Moscato stated, “It is official, and congratulations to all
current shareholders and any new shareholders who purchase GNBT
stock through October 30, 2019. This dividend and our Nasdaq
up-listing, which is currently in review, highlight the end of our
3-phase plan put forth to shareholders in January 2017 to transform
GNBT into an integrated life science and healthcare company with a
focus on end to end solutions for physicians and patients who
battle chronic, costly, and debilitating diseases like arthritis,
diabetes, and cancer. Additionally, on the pay date, I will be
retiring the nearly 21 million pool shares to significantly limit
the dilution effect of the dividend on shareholders. These events
are the catalysts in furthering our acquisition strategy, and we
have a number of new announcements slated over the coming weeks
that will further our mission! It is exciting times for Generex and
our shareholders, and we look forward to continued growth and
execution for our long-term plans.”
Mr. Moscato, stated, “Generex has been a leader in immunotherapy
for nearly 20 years, with a wealth of clinical experience
developing li-Key Hybrid immunotherapy vaccines that activate the
CD4 and CD8 T-Cell immune response to attack tumors. We have
completed one of the largest cancer immunotherapy trials ever with
a 300-patient trial evaluating our HER-2/neu vaccine AE37 for the
prevention of breast cancer recurrence. The results of that trial
have led to a clinical trial in triple negative breast cancer
combining AE37 with Merck’s PD-1 inhibitor
Keytruda® for the treatment of triple negative
breast cancer. By merging NuGenerex Immuno-Oncology with the public
vehicle, we are unlocking the value of our multimillion-dollar
investment in the li-Key technology and the development of AE37 and
other immunotherapeutic peptide vaccine products.”
“Further, we have plans to expand the clinical development of
AE37 in combination with the FDA approved checkpoint inhibitors for
the treatment of several cancers that express HER-2/neu including
prostate, bladder, urothelial, and renal cancers. We also plan to
reactivate our melanoma program with li-Key hybrids that target the
melanoma tumor biomarkers, GP100 and TYR.”
In a recent press release, Generex
Biotechnology Corporation (www.generex.com) (GNBT)
announced a merger transaction with a public company that is DTC
eligible and current with its SEC filings to serve as a vehicle for
the quotation of the common stock of its subsidiary NuGenerex
Immuno-Oncology (NGIO) as an independent, publicly traded company.
Generex is in the process of finalizing its annual report on Form
10-K, which will be filed in the coming days. The Form 10-K will
include the audited financial statements for the legal
documentation and Super Form 8-K filing for the merger of NGIO with
the public vehicle. “We expect that NuGenerex Immuno-Oncology will
be quoted on a public exchange by the end of November, and the 1:4
shareholder dividend that was paid to Generex shareholders in
February 2019 will be converted into public shares shortly
thereafter.”
Generex has positioned its wholly-owned cancer subsidiary
NuGenerex Immuno-Oncology to be merged with the public company,
thereby completing the company’s go-public strategy to realize the
value of the Ii-Key technology and AE37 immunotherapeutic vaccine
program. NGIO is currently enrolling a Phase II trial to establish
the recommended biologic dose for AE37 Peptide Vaccine in
combination with Keytruda® (Pembrolizumab) that
will enhance the tumor-specific immune response and demonstrate
efficacy in patients with advanced triple-negative breast cancer
(NSABP FB-14); the trial is currently screening and
enrolling patients at multiple clinical research sites.
“With the merger with this public company, we will not only have
the vehicle for the NGIO listing, but we will also have a platform
to incorporate additional companies, technologies, and
immunotherapy products to augment the li-Key technology and advance
our efforts in the field of cancer immunotherapy. I am happy that
our GNBT shareholders will have the opportunity to realize the
benefits of the NGIO stock dividend we paid at the beginning of the
year and, as always, we will strive to continuously build value for
our shareholders in Generex and now in NuGenerex
Immuno-Oncology.”
We expect that NuGenerex Immuno-Oncology will be quoted on a
public exchange by the end of November, and the 1:4 shareholder
dividend that was paid to Generex shareholders in February 2019
will be converted into public shares shortly thereafter.
About Generex Biotechnology Corp.Generex
Biotechnology is an integrated healthcare holding company with
end-to-end solutions for patient centric care from rapid diagnosis
through delivery of personalized therapies. Generex is building a
new kind of healthcare company that extends beyond traditional
models providing support to physicians in an MSO network, and
ongoing relationships with patients to improve the patient
experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
About Olaregen TherapeutixOlaregen Therapeutix,
Inc. is a regenerative medicine company focused on the development,
manufacturing and commercialization of products that fill unmet
needs in the current wound care market. Generex aims to provide
advanced healing solutions that substantially improve medical
outcomes while lowering the overall cost of care. Olaregen's first
product introduction, Excellagen (flowable
dermal matrix) is a topically applied product for dermal wounds and
other indications. Excellagen is a FDA 510K
cleared device for a broad array of dermal wounds, including
partial and full thickness wounds, pressure ulcers, venous ulcers,
diabetic ulcers, chronic vascular ulcers, tunneled/undermined
wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery,
post-laser surgery, podiatric, wound dehiscence), trauma wounds
(abrasions, lacerations, second-degree burns and skin tears) and
draining wounds, enabling Olaregen to
market Excellagen in multiple vertical markets.
Additionally, Excellagen can serve as an
Enabling Delivery Platform for pluripotent stem cells,
antimicrobial agents, small molecule drugs, DNA-Based Biologics,
conditioned cell media and peptides. Olaregen's initial focus will
be in advanced wound care including diabetic foot ulcers (DFU),
venous leg ulcers and pressure ulcers. Future products focusing on
innovative therapies in bone and joint regeneration comprise the
current pipeline. Generex's mission is to become a significant
force in regenerative medicine and advance the science of
healing.
About our Service-Disabled Veteran-Owned Small Business
(SDVOSB)This a Service-Disabled Veteran-Owned Small
Business (SDVOSB) that specializes in the sale, marketing, and
distribution of innovative medical products through a nationwide
network of veteran owned distribution services.
About Pantheon MedicalPantheon Medical is a
manufacturer of a physician friendly, “all-in-one”, integrated kit
that includes plates, screws, and tools required for orthopedic
surgeons and podiatrists conducting foot and ankle surgeries.
Generex is developing and submitting several new product lines to
the FDA which will include cannulated surgical screws, plates, and
implants.
About MediSource PartnersMediSource Partners is
a 10-year-old private company, currently contracted with over 25
vendors (including Pantheon Medical) for nationwide distribution of
implants and devices for spine, hips, knees, foot, ankle, hand, and
wrist surgeries. Additional product lines include biologics (blood,
bone, tissue, stem cells), durable medical equipment, and soft
goods. Generex also supplies kits to process bone marrow aspirates
and platelet rich plasma biologics at the time of surgery.
Conclusion
Generex Biotechnology share price has been continually rising as
the company is positioning for several major achievements in 2019
and beyond. There are risks associated with all drug development,
but navigating any drug through the challenging FDA approval, can
create remarkably high valuations and share prices. Generex offers
the additional advantage of diversification of potentially large
revenues from several different profit centers other than drug
development. Generex Biotechnology is showing early signs of very
strong revenue reversal and of being the new rising star of
biotech. Generex warrants a close look and early positioning before
revenues and developments advance further. An interesting note is
that small investors have the advantage of being able to purchase
shares now while larger institutional investors typically cannot
buy any shares that are under $5.00.
Legal Disclaimer:
Except for the historical information presented herein, matters
discussed in this release contain forward-looking statements that
are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Emerging MicroCaps or BioResearchAlert or its
principals may have been compensated for its services in the form
of cash-based compensation. The Information contains
forward-looking statements, i.e. statements or discussions that
constitute predictions, expectations, beliefs, plans, estimates, or
projections as indicated by such words as ''expects,'' ''will,''
''anticipates,'' and ''estimates''; therefore, you should proceed
with extreme caution in relying upon such statements and conduct a
full investigation of the Information and the Profiled Issuer as
well as any such forward-looking statements.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex
claims the protection of the safe harbor for forward-looking
statements that is contained in the Private Securities Litigation
Reform Act.
Disclosure: I/we have no positions in any
stocks mentioned, and no plans to initiate any positions within the
next 72 hours.
SOURCE: Seeking Alpha
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2023 to Mar 2024